Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

Trial Profile

Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RASTS

Most Recent Events

  • 01 Dec 2021 Primary endpoint (Baseline to Month 3 Change in Total Power Doppler Synovitis Score of 34 Joints (Range 0 - 102) [ Time Frame: Baseline, 3 Month ]) has been met, as per results published in the Clinical Rheumatology.
  • 01 Dec 2021 Results assessing to determine if baseline or 4-week PDUS changes in rheumatoid arthritis patients started on intravenous tocilizumab can predict 12-week and/or 24-week changes in disease activity and identify which patients may need to titrate TCZ dosage from 4 mg/kg to 8 mg/kg, published in the Clinical Rheumatology.
  • 23 May 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top